Title: Assessing Electronic Cigarette Nicotine Flux

NCT #: NCT04378907

Document date: 05/17/2022

Document Type: Informed Consent Form

RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM

STUDY TITLE: Assessing Electronic Cigarette Nicotine Flux

VCU INVESTIGATOR: Alison Breland, PhD, Associate Professor of Psychology

SPONSOR: National Institutes of Health/Food and Drug Administration

ABOUT THIS CONSENT FORM

You are being invited to participate in a research study. It is important that you carefully think about whether being in this study is right for you and your situation.

This consent form is meant to assist you in thinking about whether or not you want to be in this study. Please ask the investigator or the study staff to explain any information in this consent document that is not clear to you. You may take home an unsigned copy of this consent form to think about or discuss with family or friends before making your decision.

Your participation is voluntary. You may decide to not participate in this study. If you do participate, you may withdraw from the study at any time. Your decision not to take part or to withdraw will involve no penalty or loss of benefits to which you are otherwise entitled.

AN OVERVIEW OF THE STUDY AND KEY INFORMATION

The purpose of this research study is to find out how different types of electronic cigarette/vape e-liquids of differing nicotine concentrations affect blood nicotine levels, use behavior (how you puff), and how you feel.

The results of this study will be used to help us better understand how electronic cigarette liquid concentrations affect blood nicotine levels, use behavior, and how you feel.

In this study, you will be asked to do the following things:

- 1. Visit the Center for the Study of Tobacco Products 4 times for approximately 3-hour study visits.
- 2. Before each visit, abstain from <u>all</u> tobacco products (cigarettes, e-cigarettes/vapes, cigars, and hookah/waterpipe) for at least 12 hours. In addition, the use of any other nicotine-containing products (like nicotine gum or the nicotine patch) is prohibited.
- 3. We will also ask you to abstain from caffeinated beverages for 1 hour before each session.
- 4. During the study sessions, we will ask you to limit your cell phone and not use it at all when you are completing study tasks.
- 5. Each session will begin with a one hour waiting period during which you will sit in the session room to allow you to get used to the setting. During this waiting period you can use your phone and/or we will provide you with a movie to watch or magazine to read.

- 6. After this 1-hr waiting period, we will take a blood pressure reading (with blood pressure cuff on your arm) and monitor your heart rate (with a device that attaches to your finger; this device will stay on your finger for the entire session). A nurse will insert an IV catheter into your arm that will stay there for the entire session. This catheter will be used to draw blood periodically (less than 1 tablespoon per sample, 5 samples).
- 7. During each session, we will ask you to respond to several questionnaires to measure how you feel before and after you use an e-cigarette.
- 8. In each session, you will receive an e-cigarette loaded with e-liquid that contains nicotine. For each session, you will not know the concentration of nicotine in the e-liquid being tested in that session. During the session we will ask you to use the electronic cigarette we provide at two separate times. The first time, we will ask you to take only 10 puffs, and we will tell you when to take each of these puffs. The second time we will ask you to use the e-cigarette however you'd like.
- 9. Each time you puff on the e-cigarette, your puffs will be limited to 2 seconds using hardware and/or a computer program.
- 10. In each session, after you have used the e-cigarette two times, we will offer you the opportunity to use either your own brand of cigarettes or your own e-cigarette/vape. If your preferred tobacco product is an e-cigarette/vape, we will ask you to bring in your own e-cigarette/vape with enough of your own brand e-liquid for the session.
- 11. At the in-person screening visit (this visit), we will ask you to provide a urine sample that we will test for nicotine (to confirm that you use tobacco products) and pregnancy (women only). Also, at this visit, we will ask to see a form of identification with your date of birth. This is to verify your age.
- 12. Three months following your final session at the laboratory, we will call or email you to complete a short follow-up survey. This survey will include questions about your recent cigarette and e-cigarette use.

Your participation in this study will last up to 12 hours. Approximately 32 individuals will participate in this study.

This study will not use your samples to sequence all or part of your DNA.

More detailed information about the study is described later in this document.

WHAT ALTERNATIVES ARE AVAILABLE?

This is not a therapeutic study. You have the alternative not to participate. If you do not feel comfortable answering questions on the computer, paper forms are available.

WHAT RISKS AND DISCOMFORTS COULD I EXPERIENCE FROM BEING IN THE STUDY? There are both risks and benefits of participating in research studies.

Risks and Discomforts

Benefits to You and Others

- 1. You may experience some discomfort during abstinence from cigarettes/e-cigarettes or vapes containing nicotine before the session or while using electronic cigarettes during the session. Side effects from products that contain nicotine can include sweating, lightheadedness, dizziness, nausea, and nervousness. These effects are less likely in individuals who use nicotine-containing products regularly. In addition, some people who use e-cigarettes have reported experiencing seizures. Some of these individuals reported a prior history of seizures or using other substances at the same time as their e-cigarette.
- This is not a treatment study, and you are not expected to receive any direct medical benefits from your participation in the study. The information from this research study may lead to a better understanding of e-cigarettes.
- 2. In some cases e-cigarette use has led to respiratory illnesses such as difficulties breathing, shortness of breath, cough, and/or chest pain before hospitalization. In some cases, e-cigarette use has led to death, although most of these cases have been related to vaping THC. In some cases symptoms of mild to moderate gastrointestinal illness such as nausea, abdominal pain, vomiting, diarrhea, or fevers or fatigue have been reported. The Centers for Disease Control and Prevention advises that e-cigarette, or vaping products are unsafe for youths, young adults, or women who are pregnant. Adults who do not currently use tobacco products should not start using e-cigarette, or vaping, products. If you use e-cigarette products, monitor yourself for all of these symptoms and promptly seek medical attention if you have concerns about your health.
- 3. The e-cigarette liquid that we give you may contain more nicotine than you usually use, although some e-cigarette users report using these liquids. Inform the study staff immediately if you experience any discomfort.
- 4. On very rare occasions, you may experience small droplets of liquid during inhalation of the electronic cigarette we provide. You may find these droplets to be unexpected and/or unpleasant. This experience has been reported by electronic cigarette users, and they report that it is an annoyance that does not appear to present any known medical danger. If this occurs, we will immediately replace the electronic cigarette device you are using.
- 5. Side effects from tobacco/nicotine abstinence can include irritability, anxiety and restlessness, excessive hunger, difficulty concentrating, and sleep disturbance. These are

- common abstinence symptoms in cigarette smokers. Though uncomfortable, these feelings are not medically dangerous.
- 6. You may also feel some discomfort when the nurse inserts or withdraws the needle, or when blood samples are taken. We try very hard to minimize your discomfort at these times, and the use of a trained nurse and sterile, disposable equipment enhances comfort while reducing the risk of bruising and infection.
- 7. Your heart rate and blood pressure may increase; if either increases above acceptable limits, your participation may be stopped for your safety.
- 8. You may find the monitoring equipment uncomfortable.
- The researchers will let you know about any significant new findings (such as additional risks or discomforts) that might make you change your mind about participating in the study.
- 10. The use of e-cigarettes involves risks that are currently unknown or unforeseeable. Using e-cigarettes may involve risks to a developing embryo or fetus that are currently unknown.

Non-Physical Risks:

- 11. Participation in research might involve some loss of privacy. There is a small risk that someone outside the study could see and misuse information about you.
- 12. The study questionnaires ask personal questions that are sensitive in nature. You may refuse to answer any question that makes you feel uncomfortable.

In general, we will not give you any individual results from the study.

Please read, or have someone read to you, the rest of this document. If there is anything you don't understand, be sure to ask the study staff.

MORE DETAILED INFORMATION ABOUT THIS STUDY

- 1. If your preferred tobacco product is cigarettes, we may take a photo of your own brand cigarettes to help us when purchasing them for your use in this study.
- 2. Each visit to the Center for the Study of Tobacco Products must be separated by at least 48 hours, and can occur no more than 2 times per week.
- 3. When you arrive for each visit, we may ask you towear a mask except when you are using the ECIG or cigarette we provide.
- 4. Before each visit, we will ask you questions about possible COVID-19 symptoms/exposure.
- 5. To verify that you have abstained from all tobacco products for at least 12 hours, we will use a simple breath test. Our tests are not perfect, but they are the only measures that we can accept to make certain that you have complied with the no tobacco/nicotine restrictions.
- 6. We use an IV catheter because participants tell us that is it more comfortable than repeated "sticks" with a needle. During each session we will take much less blood than the amount you would give in a single donation at a blood drive. Inserting a catheter can be challenging for some individuals with smaller veins or veins that are harder to see. In this laboratory we will attempt to insert a catheter no more than three times in one day and, if all three attempts are unsuccessful, we will discontinue the session and pay you for the time that you spent complying with study conditions before the session began (\$15) and also for the time you spent in the laboratory (\$15/hr).
- 7. The liquid will contain varying amounts of nicotine, including no nicotine. You will not know the concentration of nicotine in the e-liquid being tested. This is called blinding and it is done so that a fair evaluation of results can be made.
- 8. At each of the two times that we ask you to use the e-cigarette, you will remain seated in a comfortable chair.
- 9. When you use the e-cigarette, you may notice that it is connected to a computer and that there are pieces of equipment attached to the e-cigarette. The computer and this equipment are measuring how you are using the e-cigarette (the size and number of puffs that you take). There may be rare instances in which the equipment we use malfunctions during a session. If this happens, we may stop the session and ask you to return on another day to repeat that session. In these instances, if the equipment malfunctions in the first half of the session, we will pay you half of the money you would have earned in that session. If the equipment malfunction occurs in the second half of the session, we will pay you the full amount for that session.

10. The research assistant conducting your session may use Zoom to communicate with you while you are in the session room. No video or audio recording will take place.

WILL I BE PAID TO PARTICIPATE IN THE STUDY?

You will be paid \$15 for completing the initial screening visit. You will be paid for the time that you are not using tobacco prior to session and for your time in the laboratory: you will receive \$75 after the first session, \$100 after the second, \$150 after the third, and \$200 after the fourth session. For the follow-up survey, you will receive \$10. In all, you can earn 550 for completing this study. All in-person visits (screening and sessions) will be paid in cash. Compensation for the follow-up survey will be paid via emailed or texted Amazon gift card.

In addition, if you are eligible to participate following this screening visit, we will give you 5 cards that have our lab information and a number/letter combination on them. The numbers/letters on the cards are linked (by us) to your name/e-mail address. You can give these cards to friends or family members who might want to participate in any of our ongoing laboratory studies that involve in-person screening visits. If someone you give a card to completes the initial survey via cstpstudies.vcu.edu, appears eligible to participate in one of our laboratory studies, attends the in-person screening visit, and brings a card back to us, we will send you an additional \$20 per returned card, paid via Amazon gift code e-mailed to you. We will not tell you who brought us the card. The cards expire after one year.

Total payments within one calendar year that exceed \$600 will require the University to annually report these payments to the IRS and you. This may require you to claim the compensation you receive for participation in this study as taxable income. VCU is required by federal law to collect your social security number. Your social security number will be kept confidential and will only be used to process payment.

WHAT HAPPENS IF I AM INJURED OR BECOME SICK BECAUSE I TOOK PART IN THE STUDY?

If you are injured by, or become ill, from participating in this study, please contact your study doctor immediately. Medical treatment is available at the Virginia Commonwealth University Health System (VCU Health System). Your study doctor will arrange for short-term emergency care at the VCU Health System if it is needed.

Fees for such treatment may be billed to you or to appropriate third party insurance. Your health insurance company may or may not pay for treatment of injuries or illness as a result of your participation in this study. To help avoid research-related injury or illness, it is very important to follow all study directions.

CAN I STOP BEING IN THE STUDY?

You can stop being in this research study at any time. Leaving the study will not affect your medical care, employment status, or academic standing at VCU or VCU Health. Tell the study staff if you are thinking about stopping or decide to stop.

If you leave the study before the final regularly scheduled visit, you will be able to keep any money that you earned in the study up to that point.

Your participation in this study may be stopped at any time by the investigator without your consent. The reasons might include:

- the investigator thinks it necessary for your health or safety
- you are found to not be eligible for the study
- the sponsor has stopped the study
- you have not followed study instructions
- administrative reasons require your withdrawal

HOW WILL INFORMATION ABOUT ME BE PROTECTED?

VCU has established secure research databases and computer systems to store information and to help with monitoring and oversight of research. Your information may be kept in these databases but are only accessible to individuals working on this study or authorized individuals who have access for specific research related tasks.

Identifiable information in these databases are not released outside VCU unless stated in this consent or required by law. Although results of this research may be presented at meetings or in publications, identifiable personal information about participants will not be disclosed.

Personal information about you might be shared with or copied by authorized representatives from the following organizations for the purposes of managing, monitoring and overseeing this study:

- The study Sponsor, representatives of the sponsor and other collaborating organizations
- Representatives of VCU and the VCU Health System
- Officials of the Department of Health and Human Services

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Website will include a summary of the results. You can search this Web site at anytime.

Samples that you provide in this study may be used to develop new tests, drugs, or other products for sale (commercial profit). You will not get any payment or share in this profit.

In the future, identifiers might be removed from the information and samples you provide in this study, and after that removal, the information/samples could be used for other research studies by this study team or another researcher without asking you for additional consent.

Certificate of Confidentiality

To help us protect your privacy, we have obtained a Certificate of Confidentiality from the National Institutes of Health. With this Certificate, the researchers cannot be forced to disclose information that may identify you, even by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. The researchers will use the Certificate to resist any demands for information that would identify you, except as explained below.

The Certificate cannot be used to resist a demand for information from personnel of the United States Government that is used for auditing or evaluation of federally funded projects or for information that must be disclosed in order to meet the requirements of the federal Food and Drug Administration (FDA).

You should understand that a Certificate of Confidentiality does not prevent you or a member of your family from voluntarily releasing information about yourself or your involvement in this research. If an insurer, employer, or other person obtains your written consent to receive research information, then the researchers may not use the Certificate to withhold that information.

WHO SHOULD I CONTACT IF I HAVE QUESTIONS ABOUT THE STUDY?

If you have any questions, complaints, or concerns about your participation in this research, contact:

Dr. Alison Breland or Dr. Thomas Eissenberg at (804) 827-3562 or at abbrelan@vcu.edu or teissenb@vcu.edu

The medically responsible investigator is Dr. Thokozeni Lipato (thokozeni.lipato@vcuhealth.org).

The researcher/study staff named above is the best person(s) to call for questions about your participation in this study.

If you have general questions about your rights as a participant in this or any other research, you may contact:

Virginia Commonwealth University Office of Research 800 East Leigh Street, Suite 3000

Box 980568

Richmond, VA 23298

Telephone: (804) 827-2157

Contact this number to ask general questions, to obtain information or offer input, and to express concerns or complaints about research. You may also call this number if you cannot reach the research team or if you wish to talk to someone else. General information about

Approved by the VCU IRB on 5/17/2022

participation in research studies can also be found at http://www.research.vcu.edu/irb/volunteers.htm.

Do not sign this consent form unless you have had a chance to ask questions and have received satisfactory answers to all of your questions.

STATEMENT OF CONSENT

I have been provided with an opportunity to read this consent form carefully. All of the questions that I wish to raise concerning this study have been answered. By signing this consent form, I have not waived any of the legal rights or benefits to which I otherwise would be entitled. My signature indicates that I freely consent to participate in this research study. I will receive a copy of the consent form for my records.

Signature Block for Enrolling Adult Participants	
Adult Participant Name (Printed)	-
Adult Participant's Signature	 Date
Name of Person Conducting Consent Discussion (Printed)	-
	Signature of
Person Conducting Consent Discussion Date Principal Investigator Signature (if different from above)	- Data
Principal Investigator Signature (if different from above)	Date